Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody

Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody

US Patent 10532096 · Granted Jan 14, 2020

Estimated economic value: $126,084,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Intralesional administration of PD-1 inhibitors for treating skin cancer2025
Non-human animals expressing humanized CD3 complex2025
Mouse having a humanized cluster of differentiation 47 gene2025
Mouse having a humanized cluster of differentiation 47 gene2025
Combination therapy to treat brain cancer2025
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD2025
Multispecific antigen-binding molecules and uses thereof2025
IL10 agonists and methods of use thereof2025
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use ther2024
Non-human animals having a humanized lymphocyte-activation gene 32024
Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins2024
Anti-CD8 antibodies and uses thereof2024